HRVAT SKI ZAVOD ZA JAVNO ZDRAVST VO Zagreb, Rockefellerova 7. KB MERKUR - SVEUČILIŠNA KLINIKA VUK VRHOVAC Dugi dol 4a, Zagreb IZVJEŠĆE ZA 2011.

Similar documents
NACIONALNI REGISTAR OSOBA SA ŠEĆERNOM BOLEŠĆU CRODIAB

Središnja medicinska knjižnica

PERCEPTION OF CVD RISK FACTORS BY DIFFERENT STAKEHOLDERS - DOCTORS, MEDICAL STUDENTS, GENERAL PUBLIC, POLITICIANS, JOURNALISTS Professor ŽeljkoReiner,

STANDARDIZED EDUCATIONAL PROGRAM IN PERSONS WITH TYPE 2 DIABETES ON ORAL HYPOGLYCEMIC THERAPY: EFFECTS ON GLYCEMIC CONTROL AND BODY MASS INDEX

AN OVERVIEW OF THE TRENDS OF CARDIOVASCULAR DISEASES IN BIH

EPIDEMIOLOGY OF OVARIAN CANCER IN CROATIA

Uloga patronažne sestre u prevenciji i liječenju šećerne bolesti

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

Diabetes Mellitus. Eiman Ali Basheir. Mob: /1/2019

SCIENTIFIC STUDY REPORT

Obesity Prevention and Control: Provider Education with Patient Intervention

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Središnja medicinska knjižnica

INCIDENCE OF CARDIOVASCULAR RISK FACTORS IN OBESE CHILDREN

Uloga obiteljskog liječnika u prepoznavanju bolesnika s neuroendokrinim tumorom

Structure of Visits Persons with Diabetes in Croatian Family Practice Analysis of Reasons for Encounter and Treatment Procedures using the ICPC-2

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION

Efficacy/pharmacodynamics: 85 Safety: 89

Diabetes Mellitus: A Cardiovascular Disease

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

The GUIDANCE study. Kamlesh Khunti University of Leicester, UK. on behalf of the GUIDANCE Study Group

Izvorni znanstveni Ëlanak / Original scientific paper

Scientific Journal of the Faculty of Medicine in Niš 2013;30(1):21-30

STROKE PATIENTS TREATED AT DEPARTMENT OF NEUROLOGY, ŠIBENIK-KNIN COUNTY GENERAL HOSPITAL,

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

ASSeSSing the risk of fatal cardiovascular disease

Case study for CME Diabetes up-to-date management

Promotive effect of comprehensive management on achieving blood glucose control in senile type 2 diabetics

What s New in Bariatric Surgery?

National Collaborative Wave 2 (Wave 9): National Diabetes Prevention and Management Wave, Month 9 Diabetes Management: Diabetes Register

Deprivation Study. The Freiburg Study

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES

Primary Prevention Patients aged 85yrs and over

Views of Elementary School Teachers towards Students with Cochlear Implants Inclusion in the Process of Education

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

The Diabetes Link to Heart Disease

Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls

The role of physical activity in the prevention and management of hypertension and obesity

Challenges in type 2 diabetes control: slipping control and weight gain

Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker

Type 2 diabetes in Tuvalu: A drug use and chronic disease management evaluation. Prepared for the Ministry of Health, Tuvalu.

Journal of Diabetes, Endocrinology and Metabolic Diseases

Davor Galetović, Ivana Olujić, Ljubo Znaor, Kajo Bućan, Dobrila Karlica, Mladen Lešin and Tihomir Sušac

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes

Središnja medicinska knjižnica

DO CHANGING DIAGNOSTIC CRITERIA FOR GESTATIONAL DIABETES INFLUENCE PREGNANCY OUTCOME?

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Clinical Study Synopsis

Presenter: Lurline Less April 2018

Analysis Plan Submission Form

Patient is healthy with no chronic disease or significant risk factors [16%].

Supplementary Table 1. Patient demographics and baseline characteristics (treated patients).

Diabetes and Weight Management: Tools to Affect Patient Outcomes

Clinical Practice Guideline Key Points

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

ESC/EAS Guidelines for the Management of Dyslipidaemias

Herpes zoster prikaz slučaja Herpes zoster case report Klaudija Gospić, Hrvoje Vuković... 74

2014/10/20. Management of Lipid Disorders Eric Klug Sunninghill, Sunward Park and CM JHB Academic Hospitals

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

DR WAFULA Z NALWA, MBCHB

Sandra Božičević dipl. ing. med. biochem, Marijana Vučić Lovrenčić, PhD Vuk Vrhovac University Clinic, Zagreb, Croatia

UNIVERSITY OF SPLIT SCHOOL OF MEDICINE. Daniel Leidinger ADHERENCE OF PATIENTS WITH DIABETES AND HYPERTENSION. Diploma thesis

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

A replacement KAMUT khorasan wheatbased diet improves the risk profile of patients with type 2 diabetes mellitus (T2DM): a randomized cross-over trial

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Središnja medicinska knjižnica

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Diabetes Control and Complications in Public Hospitals in Malaysia

Professional development requirements for delivery of Lift for Life

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

New ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Lipids. Professor Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC

The State of Play of Diabetes Indicators

Relationship of Plasma Creatine Kinase and Cardiovascular Function in Myocardial Infarction

PRIMARY TAPETORETINAL DYSTROPHIES AS THE CAUSE OF BLINDNESS AND IMPAIRED VISION IN THE REPUBLIC OF CROATIA

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Results of the liberalisation of Medisave for a population-based diabetes management programme in Singapore

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY

Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure

Management of Diabetes in 2011: Cases

FOR PERSONAL USE ONLY

2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE

INCIDENCE OF DIABETIC EYE DISEASE IN ACCORDANCE WITH DURATION, GLYCEMIC CONTROL, BLOOD AND OCULAR PRESSURE

DMEP Study Section 1 1

A pilot Study of 25-Hydroxy Vitamin D in Egyptian Diabetic Patients with Diabetic Retinopathy

Dr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD

Cardiovascular disease - from management to prevention

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Diabete: terapia nei pazienti a rischio cardiovascolare

Josip Lukenda 1 *, Boris Starčević 2, Diana Delić Brkljačić 3, Zrinka Biloglav 4

PLEASE REMEMBER TO BRING TO EACH APPOINTMENT

Insulin resistance influences 24h heart rate and blood pressure variabilities and cardiovascular autonomic modulation in normotensive healthy adults

INCIDENCIJA I MORTALITET OD RAKA U CENTRALNOJ SRBIJI CANCER INCIDENCE AND MORTALITY IN CENTRAL SERBIA 2006

American Academy of Insurance Medicine

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Glycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men:

Transcription:

HRVAT SKI ZAVOD ZA JAVNO ZDRAVST VO Zagreb, Rockefellerova 7. - KB MERKUR - SVEUČILIŠNA KLINIKA VUK VRHOVAC Dugi dol 4a, Zagreb IZVJEŠĆE ZA 2011. Nacionalni registar osoba sa šećernom bolešću CroDiab National Diabetes Registry CroDiab Autori: Dr. sc. Tamara Poljičanin, dr. med. Prof. dr. sc. Željko Metelko, dr. med. Mario Šekerija, dr. med. Zagreb, 2012.

IZVJEŠĆE ZA 2011. GODINU SAŽETAK osnovan je 2000. godine s ciljem unapređenja zdravstvene zaštite osoba sa šećernom bolešću, utvrđivanja prevalencije i incidencije šećerne bolesti i njenih akutnih i kroničnih komplikacija, praćenja morbiditeta i mortaliteta, te osnovnih kliničkih pokazatelja na nacionalnoj razini. Prijava je od 2004. godine obavezna za sve liječnike primarne i sekundarne zdravstvene zaštite koji u svojoj skrbi imaju osobe sa šećernom bolešću. U Republici Hrvatskoj su, prema podacima Centralnog zdravstvenog informacijskog sustava (CEZIH), u 2011. godini registrirane 230.084 punoljetne osobe s dijagnozom šećerne bolesti. U CroDiab registru sveukupno je registrirano 109.109 bolesnika, a u 2011. godini pristigle su prijave za 37.825 osoba sa šećernom bolešću. Od prijavljenih bolesnika njih 6,05% klasificirano je kao tip 1, 92,86% kao tip 2, 0,74% kao drugi tip i 0,34% kao gestacijski dijabetes. Od svih bolesnika, 52,82% bolesnika liječeno je oralnim hipoglikemicima, 19,11% oralnim hipoglikemicima u kombinaciji s inzulinom, 26,53% samo inzulinom dok je 1,55% bolesnika liječeno samo osnovnim dijetetskim mjerama. Regulacija glikemije bila je dobra (HbA1c<6,5%) u 22,26%, uvjetno zadovoljavajuća (6,5%<HbA1c<7,5%) u 35,26%, a loša (HbA1c>7,5%) u 42,49% bolesnika uz prosječne vrijednosti svih bolesnika od (aritmetička sredina ± standardna devijacija) HbA1c 7,49 ± 1,38, glikemije natašte 9,45 ± 3,05 te postprandijalne glikemije 12,12 ± 4,27. SUMMARY Croatian National Diabetes Registry was established in 2000 with the aim of improving health care of persons with diabetes mellitus, assessing the prevalence and incidence of diabetes mellitus and its acute and chronic complications, monitoring morbidity, mortality and other clinical care quality indicators on a national level. Since 2004, registration has been mandatory for all general practitioners and hospital physicians treating persons with diabetes mellitus. The overall number of patients registered in the CroDiab registry is 109,109, while in 2011 registrations were collected for 37,825 patients. There were 6.05% of patients with type 1 diabetes, 92.86% with type 2, 0.34% with gestational diabetes and 0.74% of those with other specific types of diabetes mellitus. Fifty-three percent of patients were treated with oral antidiabetic agents, 19% with oral antidiabetics and insulin, 26.5% with insulin alone, while 1.5% of patients were treated only with diet and physical activity. Glycemic regulation was good (HbA1c<6.5%) in 22.26% of cases, intermediate (6.5 %< HbA1c<7.5%) in 35.26% and poor (HbA1c>7.5%) in 42.49% of patients with average value (mean±standard deviation) of HbA1c in the entire group of patients being 7.49±1.38, fasting glucose 9.45±3.05, and postprandial glucose 12.12±4.27. According to the official data from Central health information system of Croatia, there were 230,084 persons with diabetes registered with their general practitioners in 2011. 2

CroDiab National Diabetes Registry CroDiab Podaci Information: KB Merkur, Sveučilišna klinika Vuk Vrhovac, Zajčeva 19, Zagreb - Clinical Hospital Merkur, Vuk Vrhovac University Clinic, Dugi dol 4a, Zagreb osnovan je 2000. godine s ciljem unapređenja zdravstvene zaštite osoba sa šećernom bolešću, utvrđivanja prevalencije i incidencije šećerne bolesti i njenih akutnih i kroničnih komplikacija, praćenja morbiditeta i mortaliteta, te osnovnih kliničkih pokazatelja na nacionalnoj razini. Nacionalni registar od velikog je značaja za planiranje preventivnih akcija i redukciju troškova u zdravstvenoj zaštiti, a ne manje važna njegova uloga je i unapređenje i osiguranje kvalitetnije skrbi bolesnicima. Prijava je od 2004. godine obavezna za sve liječnike primarne i sekundarne zdravstvene zaštite koji u svojoj skrbi imaju osobe sa šećernom bolešću i koji su dužni prijaviti sve BIS podatke (Basic information sheet; definiran od Svjetske zdravstvene organizacije i Međunarodne dijabetološke federacije kao optimalan skup informacija potrebnih za praćenje i unapređenje kvalitete dijabetološke skrbi) za sve osobe sa šećernom bolešću u svojoj skrbi, svake godine jedanput. Predefinirani načini prikupljanja podataka su za dijabetološke centre - CroDiab NET aplikacijski program ili CroDiab WEB on-line sustav, a za liječnike primarne zdravstvene zaštite - CroDiab WEB on-line sustav. Korisnici kojima je nedostupno korištenje informacijske tehnologije popunjavaju papirnate BIS obrasce te ih dostavljaju poštom. Dijagnostički entiteti obuhvaćeni praćenjem definirani su prema MKB-10 klasifikaciji (E10-E14 - šećerna bolest tip 1, tip 2, drugi, malnutricijski, nespecificirani, G63.2 - polineuropatije kod bolesti svrstanih drugamo, H36 - dijabetička retinopatija) i ICF klasifikaciji (b540 opće metaboličke funkcije, b279 dodatne osjetne funkcije, druge određene i neodređene, b298 osjetne funkcije i bol, druge određene). U dinamičnom CroDiab registru sveukupno je registrirano 109.109 živih bolesnika, a u 2011. godini pristigle su prijave za 37.825 osoba sa šećernom bolešću. Prijave su pristigle za 9.369 bolesnika iz 285 centara primarne, 11.599 bolesnika iz 13 centara sekundarne i 18.121 bolesnika iz 4 centra tercijarne zdravstvene zaštite. Od prijavljenih bolesnika njih 6,05% klasificirano je kao tip 1, 92,86% kao tip 2, 0,74% kao drugi tip i 0,34% kao gestacijski dijabetes. 52,82% bolesnika liječeno je oralnim hipoglikemicima, 19,11% oralnim hipoglikemicima u kombinaciji s inzulinom, 26,53% samo inzulinom dok je 1,55% bolesnika liječeno samo osnovnim dijetetskim mjerama. Regulacija glikemije bila je dobra (HbA1c<6,5%) u 22,26%, uvjetno zadovoljavajuća (6,5%<HbA1c<7,5%) u 35,26%, a loša (HbA1c>7,5%) u 42,49% bolesnika uz prosječne vrijednosti HbA1c u svih bolesnika (aritmetička sredina ± standardna devijacija) od 7,49 ± 1,38, glikemije natašte 9,45 ± 3,05 te postprandijalne glikemije 12,12 ± 4,27. Prosječne vrijednosti u svih bolesnika (aritmetička sredina ± standardna devijacija) ostalih najznačajnijih rizičnih faktora za razvoj kroničnih komplikacija bolesti bile su: ITM 30,02 ± 5,24 kg/m 2, sistolički krvni tlak 136,30 ± 17,05 mmhg, dijastolički krvni tlak 81,60 ± 8,81 mmhg, ukupni kolesterol 5,27 ± 2,57 mmol/l, HDL - kolesterol 1,35 ± 0,37 mmol/l, LDL - kolesterol 2,98 ± 1,28 mmol/l, trigliceridi 2,02 ± 2,03 mmol/l, a 14,68% bolesnika bili su pušači. Tijekom 2010. i 2011. godine broj prijavljenih bolesnika pokazuje trend smanjenja, što je posljedica organizacijskih problema. Tijekom 2011. godine uspostavljena je razmjena podataka s bazom podataka Centralnog zdravstvenog informacijskog sustava Hrvatske (CEZIH). U Republici Hrvatskoj, prema navedenim podacima, kod izabranog obiteljskog liječnika registrirane su 230.084 punoljetne osobe s dijagnozom šećerne bolesti (E10-E14). 3

Slika 1. Broj godišnje prijavljenih bolesnika u CroDiab registru Figure 1. Number of patients annually registered in the CroDiab Registry Slika 2. Broj bolesnika u registru na kraju godine Figure 2. Number of patients in the CroDiab Registry at the end of the year Slika 3. Regulacija glikemije prema HbA1c udio bolesnika Figure 3. Regulation of glycaemia according to HbA1c percentage of patients 4

Tablica 1. Indikatori šećerne bolesti - Table 1. Diabetes indicators EPIDEMIOLOGIJA ŠEĆERNE BOLESTI EPIDEMIOLOGY OF DIABETES Incidencija tip 1 šećerne bolesti, dob 0-14 godina Annual incidence of Type 1 Diabetes by age/100,000 population 0-14 yrs 5 Ispitivanje HES_data 1995-2003 (female/male per year) Prevalencija šećerne bolesti Prevalence of diabetes mellitus/1,000 population Ispitivanje HES_ data 1997 Prevalencija oštećene tolerancije glukoze (poremećene glukoze na tašte) Prevalence of persons with impaired glucose tolerance RIZIČNI FAKTORI ZA RAZVOJ KOMPLIKACIJA (U OSOBA SA ŠEĆERNOM BOLEŠĆU) RISK FACTORS FOR COMPLICATIONS (IN PEOPLE WITH DIABETES) HbA1c: Udio bolesnika s vrijednostima u posljednjih 12 mjeseci HbA1c: Percent tested in last 12 months HbA1c: Udio bolesnika s HbA1c >7,5% u posljednjih 12 mjeseci - HbA1c: Percent >7.5% in last 12 months Lipidi: Udio bolesnika s profilom lipida u posljednjih 12 mjeseci - Lipids: Percent with lipid profile in last 12 months Lipidi: Udio bolesnika s vrijednostima ukupnog kolesterola >4,5 mmol/l Lipids: Percent of those tested with total cholesterol >4.5 mmol/l Lipidi: Udio bolesnika s vrijednostima LDL >2.5 mmol/l Lipids: Percent with LDL >2.5 mmol/l Lipidi: Udio bolesnika s vrijednostima HDL <1.00 mmol/l Lipids: Percent with HDL <1.00 mmol/l Lipidi: Udio bolesnika s vrijednostima triglicerida >1.7 mmol/l Lipids: Percent with triglycerides >1.7 mmol/l Mikroalbuminurija: Udio bolesnika testiranih u posljednjih 12 mjeseci Microalbuminuria: Percent tested in last 12 months Mikroalbuminurija: Udio bolesnika s mikroalbuminurijom u posljednjih 12 mjeseci Microalbuminuria_ Percent with microalbuminuria in last 12 months Krvni tlak: Udio bolesnika s vrijednostima u posljednjih 12 mjeseci Blood pressure: Percent tested in last 12 months Krvni tlak: Udio bolesnika s RR>130/80 u posljednjih 12 mjeseci Blood pressure: Percent with BP >130/80 in last 12 months 8.87/100000 djevojčica/ godinu 8.47/100000 dječaka/ godinu 65,49/1000 (dob 18-65) ( 89/1000 dob 20-80) Ispitivanje HES_ data 1997 45/1000 (dob 18-65) CroDiab (DiabCare System)_2011 23,92% CroDiab (DiabCare System)_2011 40,34% CroDiab (DiabCare System)_2011 33,23% CroDiab (DiabCare System)_2011 77,87% CroDiab (DiabCare System)_2011 73,32% CroDiab (DiabCare System)_2011 15,45% CroDiab (DiabCare System)_2011 55,52% CroDiab (DiabCare System)_2011 3,85% CroDiab (DiabCare System)_2011 27,70% CroDiab (DiabCare System)_2011 41,13% CroDiab (DiabCare System)_2011 62,17% Udio bolesnika koji puše Percent of persons with diabetes who are smoking CroDiab (DiabCare System)_2011 12,47% Udio bolesnika sa ITM 25 kg/m 2 ( 30 kg/m 2 ) Percent with BMI 25 kg/m 2 ( 30 kg/m 2 ) CroDiab (DiabCare System)_2011 82,87% (40,34%)